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Background: Dengue fever is the most important arthropod born viral disease of public health significance.
Although most patients suffer only from flu-like symptoms, a small group of patient experiences more severe forms
of the disease. To contribute to a better understanding of its pathogenesis this study aims to identify proteins
differentially expressed in a pool of five viremic plasma from severe dengue patients relative to a pool of five
non-severe dengue patients.
Results: The use of Isotope Coded Protein Labeling (ICPL™ ) to analyze plasma depleted of twenty high-abundance
proteins allowed for the identification of 51 differentially expressed proteins, which were characterized by mass
spectrometry. Using quantitative ELISA, three of these proteins (Leucine-rich glycoprotein 1, Vitamin D
binding-protein and Ferritin) were confirmed as having an increased expression in a panel of severe dengue
plasma. The proteins identified as overexpressed by ICPL™ in severe dengue plasma involve in clear up action after
cell injury, tissue coherence and immune defense.
Conclusion: This ICPL™ study evaluating differences between acute severe dengue plasmas and acute non-severe
dengue plasmas suggests that the three proteins identified are overexpressed early in the course of the disease.
Their possible use as biomarkers for the prognostic of disease severity is discussed.Background
Dengue virus (DV) is a tropical mosquito-born flavivirus
(family Flaviviridae) which infects an estimated 50 to
100 million people per year in tropical and subtropical
areas. After an incubation period of 3–7 days, symptoms
start suddenly and follow three phases: the febrile/acute
phase, the critical phase and the recovery phase. Clinical
manifestations of the febrile phase include biphasic fever,
body pain, maculopapular rash and minor hemorrhages
[1,2]. For a small proportion of patients, essentially chil-
dren and young adults, the critical phase corresponds to
the appearance of more severe symptoms, the dengue
hemorrhagic fever (DHF), with or without Dengue shock
syndrome (DSS). The pathogenesis of DHF/DSS has not
been fully elucidated although several hypotheses have
been proposed [3].
Immune components, and in particular antibodies,
have been associated with pathogenicity through several* Correspondence: frederic.bedin@biomerieux.com
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reproduction in any medium, provided the ormechanisms. Antibody-dependent enhancement of a
secondary infection, immune complex formation and
complement activation, cross-reactivity with proteins
such as endothelial cells or coagulation proteins, inflam-
matory activation or apoptosis are the mechanisms pro-
posed for antibody-mediated immunopathogenesis [4-7].
Moreover, several authors have reported that antibodies
also play a central role in allergic processes leading to
hemorrhagic syndrome [8,9].
Other immune components including memory T-cells,
innate immunity effectors and complement factors have
been shown to modulate the outcome as well [10,11].
The dengue non structural protein 1 (NS1) can also par-
ticipate to the pathogenicity in cooperation with the
complement proteins [10].
No specific antiviral treatment for DF and DHF exists
at the moment. Available therapies are symptomatic and
are administered to correct and control the clinical man-
ifestations of hemorrhages and shock. Early diagnosis of
virus infection and successful prognosis of DFral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment. Commonly used laboratory diagnosis methods
consist of virus isolation, viral nucleic acid amplification,
detection of viral antigen (NS1) or detection of anti-
dengue antibodies (IgG and/or IgM). No test to monitor
and predict disease severity and outcome is currently
available.
The identification of proteins specifically present in
plasma before DHF/DSS symptoms appearance may lead
to the development of new biomarkers for prognosis.
Quantitative or semi-quantitative proteomic approaches
such as SILAC (Stable-Isotope Labeling by Amino acids
in Cell culture) or ICPL™ (Isotope Coded Protein La-
beling ™) are potentially useful to find pattern of protein
markers differentially expressed for a given disease
[12,13].
In the present study, ICPL™ has been applied to pro-
file the protein expression differences existing between
non-severe (DF) and severe dengue (SD) plasma samples
taken early in the course of the disease. Quantitative
ELISA were performed to confirm the proteomic data.
The identification of these markers might contribute to
improve prognosis of severe dengue and also patient
care and management.
Results
Preparation and controls of sample pools for ICPL™
Two groups of five plasma specimens (28 μL each; total
volume of 140 μL), representative either of DF or SD,
were constituted. The composition of each group is
summarized in Table 1. All plasma came from subjects
identified as having a secondary infection to dengue
virus serotype 2 (DV2) and were taken between the
onset and the defervescence, which corresponds to the
beginning of the critical phase. The criteria used to de-











SD 10 4 F Pos. W Pos. Yes
12 3 F Pos. W Pos. Yes
13 2 M Pos. N Pos. Yes
11 2 M Pos. N Pos. Yes
14 5 M Pos. NT Pos. Yes
DF 9 3 F Pos. N Pos. Yes
13 3 F Pos. W Pos. Yes
10 3 M Pos. N Pos. Yes
9 4 M Pos. W Pos. Yes
12 5 M Pos. W Pos. Yes
(a) Gender. F : female, M : male. (b) Pos. : DV2 detected in sample. (c) Level of
specific IgM in sample. W : weak, N : not detected, NT : not tested. (d) Pos.: NS1
detected in sample.based on the patient medical record and, when possible,
on the immunoglobulin M (IgM)/IgG specific level. All
samples were both positive for the presence of virus and
for the presence of NS1 protein, indicating they were
taken during the acute phase of the disease. For some of
the plasma samples, only a low level of IgM was found.
The sex ratio (M/F=3/2), the age (9–14 years old), and
the collection day after onset (2–5 days) were similar be-
tween the two groups. All the SD patients were hospita-
lized and presented signs of plasma leakage and
hemorrhages [3]. No comorbidity was reported.
After depletion of the twenty most abundant proteins
using immunodepletion columns (Proteoprep20, Sigma),
each pool was controlled on polyacrylamide gel after an
EZBlue dying. As an example, the depletion of the
serum albumin was estimated around 98% (data not
shown).
Identification of differentially expressed proteins by
ICPL™ and MS/MS
In ICPL analysis, the relative expression is measured
using the H/L ratio which corresponds to the global
average ratio of peptides labelled with heavy (H) or light
(L) reagent, as explained in the Material and Methods
section. Among the 124 proteins identified by mass
spectrometry after ICPL™ experiment, only 51 had a
H/L ratio calculated with a minimum of two peptides.
For another group of 18 proteins, the H/L ratio was cal-
culated with an unique peptide. For these proteins the
results were considered as not significant. For a third
group of 55 proteins, no information on the relative
quantity was available. These two last groups were con-
sequently excluded from subsequent analysis.
The results obtained for the 51 proteins with reliable
data are summarized on the Table 2. An average H/L
ratio (cf. Average column) higher than 1 meant that the
signal obtained on SD pool was higher than the signal
monitored for the DF pool. A ratio lower than 1 meant
that the signal was higher for DF samples. The mean
(m) of all these ratios and the corresponding standard
deviation (s) were 1.4 and 0.83, respectively. Only four
proteins (Leucine-rich alpha-2 glycoprotein 1, Galectin 3
Binding-Protein, C-Reactive Protein and the Ferritin
Light-chain) had an average H/L ratio higher than 2.23,
corresponding to (m+1 s). However, in order to increase
the probability to find potential biomarkers for severe
dengue, we choose to include three additional proteins
(Vitamin D Binding-Protein, Afamin and Fibronectin).
For these proteins, the average ratio was higher than 1.6.
The Ferritin Light chain with an average ratio of 5.75
had the highest value. Quite the opposite, three proteins,
Peroxiredoxin-2, Haptoglobin and Complement compo-
nent C7 had an average ratio lower than 0.57, corre-
sponding to (m-1 s). Haptoglobin and Complement
Table 2 Host proteins identified and relative quantification by ICPL™
Protein names and species Accession number H/La Averageb Max. Averagec
Peroxyredoxin 2; Homo sapiens P322119 9 0,33 0,08
Haptoglobin; Homo sapiens P00738 13 0,43 0,150
complement C7; Homo sapiens P10643 8 0,48 0,030
Apolipoprotein A; Homo sapiens P06727 3 0,68 0,310
Fibrinogen Alfa chain Homo sapiens P02671 4 0,79 0,030
Apolipoprotein E; Homo sapiens P02649 6 0,8 0,0140
Serum amyloïd A Protein; Homo sapiens P02735 7 0,92 0,070
Fibrinogen beta chain Homo sapiens P002675 9 0,93 0,050
Inter alpha-trypsin inhibitor H1 Homo sapiens P19827 7 0,94 0,230
Complement facteur H protéine; Homo sapiens Q03591 14 0,95 0,140
Inter alpha-trypsin inhibitor H2; Homo sapiens P19823 15 0,98 0,27
Fibrinogen gamma chain; Homo sapiens P02679 3 0,99 0,01
Vitronectin; Homo sapiens P04004 2 1 0,1
Complement facteur B; Homo sapiens P00751 8 1,06 0,1
Complement C4; Homo sapiens POCOL4 3 1,06 0,304
Serum Albumin; Homo sapiens P02768 27 1,09 0,18
alpha-2 antiplasmin; Homo sapiens P08697 5 1,18 0,203
Antithrombin-III; Homo sapiens P01008 16 1,23 0,13
Apolipoprotein-A1; Homo sapiens P02647 74 1,24 0,21
Retinol binding-protein 4; Homo sapiens P02753 5 1,24 0,13
Prothrombin; Homo sapiens P00734 4 1,26 0,15
Complement factor 1; Homo sapiens P05156 3 1,27 0,02
Beta-2 microglobulin; Homo sapiens P61769 3 1,27 0,05
Ig alpha-1 chain C Homo; sapiens P01876 2 1,27 0,042
Hemopexin; Homo sapiens P02790 28 1,27 0,14
Alpha-1B glycoprotein; Homo sapiens P04217 4 1,28 0,08
Serum Amiloid A4 protein; Homo sapiens P35542 6 1,29 0,14
Kininogen-1; Homo sapiens P01042 3 1,3 0,346
Ig Mu chain C; Homo sapiens P01871 2 1,3 0,057
Cysteine-rich secreted protein 2; Homo sapiens P16562 2 1,3 0,212
Zinc-alpha-2 glycoprotein; Homo sapiens P25311 7 1,3 0,12
Extracellular matrix protein 1 Homo sapiens Q16610 2 1,32 0,057
Pigment epithelium-derived factor; Homo sapiens P36955 3 1,35 0,1
Complement C3; Homo sapiens P01024 7 1,37 0,19
Attractin; Homo sapiens O75882 4 1,38 0,2
Complement-facteur H-related protein 2; Homo sapiens P36980 2 1,41 1,443
Apolipoprotein B-100; Homo sapiens P04114 6 1,43 0,26
Complement facteur H; Homo sapiens P08603 24 1,46 0,41
Alpha-1 antichemoptrypsin; Homo sapiens P01011 6 1,48 0,2
Angiotensinogen; Homo sapiens P01019 4 1,54 0,25
Histidin-rich glycoprotein; Homo sapiens P04196 2 1,54 1,259
Inter-alpha trypsin inhibitor chain H4; Homo sapiens Q14624 5 1,54 0,09
Serum-amyloïd P-component; Homo sapiens P02743 15 1,56 0,23
Clusterin; Homo sapiens P10909 7 1,57 0,25
Vitamine D Binding-protein; Homo sapiens P02774 13 1,63 0,75
Afamin; Homo sapiens P43652 6 1,85 0,34
Fibronectin; Homo sapiens P02751 9 1,99 0,28
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Table 2 Host proteins identified and relative quantification by ICPL™ (Continued)
Leucine-rich alpha-2 glycoprotein 1; Homo sapiens P02750 2 2,26 0,884
Galectin-3 binding-protein; Homo sapiens Q08380 5 2,66 0,26
C-reactive protein; Homo sapiens P02741 3 3,87 0,365
Ferritin light chain; Homo sapiens P02792 5 5,75 1,7
(a) Number of heavy and light peptide identified for a protein. (b) Global average of the H/L ratio. (c) H/L ratio standard deviation. Lines in italic indicate the
selected proteins.
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fectly removed by the kit of depletion. Thus, the
Peroxiredoxin-2 was the unique protein which had a
ratio lower than 0.57. Finally, the selected proteins were
Peroxyredoxin-2, Vitamin D Binding-Protein (VitDBP),
Afamin, Fibronectin, Leucine-rich alpha-2 glycoprotein
1 (LRG1), Galectin 3 Binding-Protein, C-Reactive Pro-
tein and Ferritin Light-chain. These proteins, with an
average ratio higher than 1.6 or lower than 0.57, repre-
sented 20% of the 51 selected proteins. The Table 2 also
gave the standard deviation (cf. Max. average column).
This standard deviation corresponded to a percentage
generally included between 10 and 30% of the average
ratio, even though sometimes it was higher: 35% for
Haptoglobin, 40-45% for Apolipoprotein A, VitDBP and
LRG1, or more for Complement factor H-related protein
or Histidine-rich glycoprotein. The seven selected pro-
teins were classified into several categories based both
on their differential expression and on their functional
significance (Table 3). They belong to a variety of func-
tional categories (transport protein, inflammatory pro-
tein, adhesion, cell organisation and interaction).
Interactions have been identified between G3BP and
Peroxiredoxin 2 or LRG1 and Fibronectin using the
STRING protein-protein interactions database (http://
string-db.org). All are soluble proteins either located in
the cytosol or secreted.
Despite depletion of the twenty most abundant pro-
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for these proteins the H/L average ratio was not consid-
ered as significant.
Validation of differentially expressed proteins by
quantitative ELISA
To confirm the ICPL™ data, specific ELISA were per-
formed using individual plasma samples from SD or DF
patients. For each pathology, between 12 and 20 speci-
mens were tested. Testing was also performed on three
healthy plasmas (not dengue virus-infected). All dengue
samples corresponded to secondary dengue infections
and had been taken between onset and defervescence
(between days 2 and 5) from patients infected with vari-
ous DV serotypes (DV1, DV2 and DV3). The patients
were between 4 and 16 years old. The M/F sex ratios for
DF and SD samples were 5/12 and 7/16 respectively.
These samples were both controlled positive for the
presence of virus by RT-PCR and for the NS1 protein by
a commercial ELISA (NS1 Platelia™). The SD patients
were hospitalized and presented signs of plasma leakage
and hemorrhages. No comorbidity was reported.
For Peroxiredoxin-2 detection, a specific ELISA was
set-up in-house. Six commercial quantitative ELISA
were used for the other proteins. For Peroxiredoxin, Afa-
min, Galectin-3 Binding Protein and C-Reactive Protein,
no significant difference was found between DF and SD
samples (data not shown). For VitDBP, Ferritin, LRG1,
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Figure 1 Comparison of protein concentration detected by
quantitative ELISA. Acute plasma from classical dengue patient
(DF), acute plasma from severe dengue patients (DHF) or healthy
plasma from non-dengue patients (HLTY) were tested by ELISA for
(a) VitDBP, (b) LRG1 and (c) Ferritin. Each value corresponds to the
mean of two experiments in duplicate.
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sion level existed and was significantly higher in SD
patients.
Discussion
Dengue is an important health problem in tropical and
sub-tropical areas. Although the pathogenesis of the dis-
ease has been studied intensively, some aspects remain
not well understood. Genome-wide expression profile
analysis on microarrays or 2D-electrophoresis protein
difference analysis in combination with MALDI-TOF/
TOF Mass Spectrometry have been used to search for
biomarkers that could serve as prognostic tools or
therapeutic targets for severe dengue. Proteins belong-
ing to the complement pathway or involving in pro-
cesses such as inflammation, signal transduction or
translation/transcription have been identified but there
is no clear consensus on their potential use in the sever-
ity prognostic [14-17]. More recently, Brasier et al. [18]
described a new pre-fractionation method on acute
dengue Venezuelan plasmas followed by a 2D-gel elec-
trophoresis in tandem with LC-MS/MS and a non-
parametric analysis. Previously unidentified biomarkers
having biological significance in process underlying se-
vere dengue such as capillary leakage or hepatic injury,
have been found.
The plasma, which corresponds to the unclotted blood
after removal of cellular components, has constant in-
timacy with different body parts and contains proteins
released by diseased tissues [19]. The comparison of cir-
culating proteins in plasma from patients developing dif-
ferent aspects of a same disease may lead to the
discovery of biomarkers for diagnosis, prognosis and dis-
ease monitoring [20]. The present study aims to identify
differences in circulating proteins during different
degrees of severity of dengue virus acute infections.
Stable isotope protein labeling combined with Mass
Spectrometry is a powerful tool to identify and relatively
quantify proteins within complex protein mixtures such
as tissue extracts or body fluids. The ICPL™ technique
allows high-throughput quantitative proteome profiling
on a global scale. It is used for protein profile compari-
son [21,22].
Here, ICPL™ was used to compare mild and severe
dengue plasmas for the identification of differentially
expressed proteins. To increase the chance of finding
low-abundance proteins the study was conducted on
plasma depleted of the twenty most abundant proteins.
For this purpose, it has previously been proven that
immune-capture columns are useful [23]. However, the
higher the number of depleted proteins is, the more im-
portant the drawback in removing associated proteins
and peptides is. This drawback could have an impact on
the list of identified markers of severity [23].
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cimen homogeneous in age, sex ratio, days of collect
after onset of symptoms and serotype would limit the
ICPL identification of idiotypic markers specific of each
individual plasma sample. It would also promote the dis-
covery of markers that should be common to all samples,
such as severe dengue markers. Although sometimes criti-
cized [24], the use of a pool instead of several separate
samples for proteomic analysis has been reported in re-
cent studies [25,26].
Three proteins, identified by mass spectrometry, were
confirmed by ELISA to have significant higher expres-
sion levels in SD plasmas. These proteins were Leucine-
Rich alpha-2 Glycoprotein 1, Ferritin and Vitamin D
Binding-Protein.
The physiological function of LRG1 is still unknown.
In 2002, O'Donnell et al. [27] have suggested a physio-
logical role in neutrophilic granulocytes. In 2006, Cum-
mings et al. [28] identified LRG1 as cytochrome c
inhibitor in sera. More recently, Codina et al. [29] have
shown that LRG1 protects against Cytc-induced lympho-
toxicity. LRG1 has also been shown to be involved in
protein-protein interaction, signal transduction, cell ad-
hesion and development. LRG1 was identified as a
serum biomarker that identifies patients with heart fail-
ure [30]. In the literature, LRG1 has never been asso-
ciated to the dengue severity. Interestingly, LRG1 has
been shown to interact with the Fibronectin also identi-
fied in the present study as being over-expressed in SD
plasmas [31].
VitDBP is a 52 kDa protein that binds to vitamin D as
well as its plasma metabolites and transports them to
target tissues. VitDBP binds monomeric actin in
addition to Vitamin D. The protein forms three
domains. The structure of VitDBP is similar to the
Human Serum Albumin [32,33]. It is presumed that the
function of VitDBP binding actin is to clear up any actin
that enters the blood stream as a result of cell injury. Its
affinity for actin monomers is high [34] and binding
involves residues from all three domains [32,33]. VitDBP
also participates to macrophage activation and chemo-
taxis. The protein has been already associated to the
pathogenesis of dengue by a Two-dimensional difference
gel electrophoresis (DiGE) analysis on Brazilian plasma
specimens [14].
Ferritin is a globular protein which serves to store
iron in a non-toxic form, and to transport it to areas
where it is required [35]. Free iron is toxic to cells be-
cause it catalyzes the formation of free radicals from re-
active oxygen species [36]. Within cells, iron is stored in
a protein complex as ferritin or hemosiderin. Ferritin
concentrations increase drastically in the presence of an
infection or with cancer [37]. The inflammatory re-
sponse may cause ferritin to migrate from the plasma tothe cells in order to deny iron to the infectious agent
[37]. The concentration of ferritin has also been shown
to increase in response to stresses such as anoxia [38].
In a previous study, high serum ferritin levels have been
demonstrated by ELISA to be a biomarker of dengue
hemorrhagic fever in Thai children [39]. Interestingly,
proteins involved in inflammatory process have often
been identified as potential markers of dengue severity
[14-17].
All these proteins are related to several functions:
transportation, adhesion and iron storage and seem to
participate in the preservation of the body homeostasis
during dengue infection.Conclusions
This is the first report of a study using ICPL™ to evalu-
ate differences between acute severe dengue plasma and
acute non-severe dengue plasma. Among 8 proteins
found having significant differential expression, we con-
firmed by ELISA that 3 proteins (Leucine-Rich alpha-2
Glycoprotein 1, Ferritin and Vitamin D Binding-Protein)
were present at higher concentrations in SD samples
early in the course of the disease. The contribution of
these proteins to disease evolution and final outcome
needs to be further investigated. Interestingly and more
importantly the study suggests that these proteins could
be used as potential markers for dengue severity and
could be part of a serological assay as an aid for better
patient stratification and disease management. Moreover,
it will be necessary to validate these biomarkers with
samples from other cohorts coming from different parts
of the globe where dengue is endemic.Methods
Plasma specimens
Plasma samples from secondary dengue-virus serotype 2
(DV2) infection were obtained from the Institut Louis
Malardé, Papeete, Tahiti (French Polynesia). These sam-
ples were collected from patients being part of retro-
spective studies reviewed and approved by the local
Medical Ethic Committee in compliance with the ethical
standards of the Declaration of Helsinki. Alternatively,
other plasma samples of mixed serotypes (DV1, DV2
and DV3) coming from the same retrospective studies,
were used in ELISA. All the samples were taken between
the onset of symptoms and the defervescence. Dengue-
negative plasma specimens were obtained from healthy
donors through the National French Bloodbank (Etablis-
sement Français du Sang, Lyon, France). Dengue sam-
ples were tested for the presence of the viral NS1
protein with the Platelia™ ELISA following the ma-
nufacturer’s instructions (BioRad, Marnes-la-Coquette,
France).
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The twenty most abundant plasma protein were
removed from 140 μL (5 plasmas × 28 μL) of the plasma
pools using ProteoPrep20 Plasma immunodepletion Kit
(Sigma Aldrich, Saint-Louis, USA) as recommended by
the manufacturer. After filtration on a 0,2 μM device,
the total proteins were quantified using the protein assay
(Bio-Rad, Marnes-la-Coquette, France).
ICPL™ and protein identification by mass spectrometry
The ICPL™ technique allows the comparative analysis of
complex samples by an isotopic labeling of the intact
proteins. ICPL™ and protein identification have been
conducted by InnovaProteomic (Rennes, France). Before
ICPL™-labeling, acetone precipitation of proteins from
either DF or DHF depleted pool of plasma was carried
out. To one volume of sample 5 volumes of acetone
cooled to −20°C were added and incubated overnight at
−20°C. Precipitated proteins were pelleted by centrifu-
gation 15 min at 15,000 g at 4°C. Pellets were washed
with cold 80% (v/v) acetone and dried. The protein con-
centration, previously determined by a Bradford assay,
was used to adjust sample concentration at 3 mg/ml in
ICPL™ lysis buffer containing 6 M Guanidine-HCl
pH8.5 (SERVA, ICPL™ Kit). For equal amounts of pro-
teins (60 μg for each sample), cysteines were alkylated
by addition of 0.4 M of iodoacetamide and differentially
labeled using the ICPL™ kit containing 12C- (light label-
ing) and 13C6–Nicotinoyloxysuccinimide (heavy labeling)
from Serva Electrophoresis GmbH (Heidelberg, Germany)
as described by the manufacturer [40]. Thereafter the
two ICPL™ labeled samples were combined and pro-
teins were precipitated by acetone to remove excess
labeling reagent. Proteins were solubilized in Laemmli
sample buffer, separated on 12% SDS-PAGE (GeBa,
Interchim) in duplicate and stained with EZblue (Sigma
Aldrich, Saint Louis, USA). After staining, the gel lanes
were cut into 20 pieces and in-gel digestion by Trypsin
was performed overnight at 37°C, according to the con-
ventional method [41]. Finally, the peptides were extracted
with 50% (v/v) acetonitrile containing 0.1% of formic acid
[42]. The extracts were evaporated using a vacuum con-
centrator. The dried peptide samples were stored at −80°C
until analysis.
Peptide separation was done by liquid chromatog-
raphy using a nanoLC Ultimate system (Dionex
GmbH, Idstein, Germany) coupled to an ion trap Es-
quire HCT ultra (Bruker Daltonics GmbH, Bremen,
Germany). Mass spectra were recorded and the quanti-
fication was operated by the WARP-LC 1.1 software.
To identify proteins, searches against the MSDB data-
base (version 2007, 148 210 sequences for human) using
Mascot 2.3 software (Matrix Science, in-house server)
were carried out via Biotools software (BrucknerDaltonic). Proteins were identified with a score higher
than 36 (p<0.05).
In order to eliminate false matches and incorrect protein
identification, search on the SwissProt-Trembl_Decoy
database was performed using the Mascot 2.3 software.
The IRMa software [43] was used to filter the results so
that the rate of false positives was lower than 1%.
The change in protein abundance was expressed by
the calculation of a ratio between the two type of labeled
peptides (heavy and light). To calculate the heavy/light
(H/L) ratios of a protein at least two unique peptides la-
beled with heavy and light reagents were chosen respect-
ively and a global average ratio was determined. For
each result, standard deviation was calculated.
Three independent analytical replicates were per-
formed for each 1D-gel band.
Quantitative ELISA
Protein quantities were measured twice in duplicate on
each DF or SD plasma specimens using commercial
ELISA. Human Ferritin and LRG1 kits were purchased
from IBL international (Hamburg, Germany) and the
Human Vitamin D binding–protein from USCN Inc.
(Wuhan, China). Protocols were performed as recom-
mended by the manufacturers. For each test a standard
curve was established with serial dilution of calibrator in
order to determine the protein concentration. Statistical
analysis were performed using the Student t test and the
GraphPadPrism 4.03 software.
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